Daily PubMed evidence board
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis.
This systematic review and meta-analysis pooled results from phase 3 randomized trials to compare immune checkpoint inhibitor (PD-[L]1) monotherapy versus…
Signal score51Research triage score
CertaintyModerate-to-low (downgraded for heterogeneity and indirectness in comparisons)Verify in full text
PMID42240993Source identifier
Research triage, not medical advice
Do not use this summary, score, or benefit-cost estimate to diagnose, treat, prescribe, or change care without reviewing the full study and consulting qualified professionals.
Verify before acting
Check full-text methods, eligibility, outcomes, risk of bias, harms, conflicts, funding, replication, and applicability.
Plain-English signal
This systematic review and meta-analysis pooled results from phase 3 randomized trials to compare immune checkpoint inhibitor (PD-[L]1) monotherapy versus combining those inhibitors with chemotherapy (chemoimmunotherapy) as first-line treatment for people with advanced non-small cell lung cancer whose tumors have high PD-L1 (≥50%). Both approaches improved survival versus chemotherapy alone, but across trials chemoimmunotherapy was associated with better overall survival and longer time before disease progression than PD-(L)1 inhibitor alone. The authors conclude chemoimmunotherapy appears to provide superior survival in this patient group, but they note prospective trials are still needed to confirm this finding and to better understand harms and patient selection.
Why it matters
- Addresses first-line treatment choice for advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression (≥50%), a common clinical decision point between PD-(L)1 inhibitor monotherapy and chemoimmunotherapy.
- Findings directly relate to overall survival (OS) and progression-free survival (PFS), outcomes that drive clinical benefit, treatment selection, and resource use in oncology care.
- If chemoimmunotherapy confers superior survival in this subgroup, treatment guidelines, prescribing patterns, and health-system budgeting for advanced NSCLC may need re-evaluation.
Primary outcomes
- Overall survival (OS)
- Progression-free survival (PFS)
Effect summary
Across 24 phase 3 trials (n=5546 patients with PD-L1-high NSCLC) both chemoimmunotherapy and PD-(L)1 inhibitor monotherapy improved OS and PFS versus chemotherapy. Reported pooled HRs versus chemotherapy: chemoimmunotherapy OS HR 0.63 (95% CI, 0.56-0.72), PFS HR 0.44 (95% CI, 0.39-0.49); PD-(L)1 monotherapy OS HR 0.74 (95% CI, 0.69-0.80), PFS HR 0.70 (95% CI, 0.65-0.76). Indirect and reconstructed individual patient analyses reported longer median OS and PFS with chemoimmunotherapy than with PD-(L)1 monotherapy (median OS ~29.2 vs 19.8 months; median PFS ~11.3 vs 6.8 months; reconstructed-patient HR for chemoimmunotherapy vs monotherapy 0.74 [95% CI, 0.66-0.82]). Subgroup tests and network/meta-regression analyses were consistent with a relative advantage for chemoimmunotherapy, though heterogeneity was substantial for some comparisons.
Benefit-cost lens
| Quick take | Meta-analysis of phase 3 RCTs suggests chemoimmunotherapy yields larger relative survival gains than PD-(L)1 inhibitor monotherapy in PD-L1 ≥50% advanced NSCLC, but absolute benefits, harms, and resource implications need local data before policy or implementation changes. |
|---|---|
| BCR anchor | 1 |
| Time horizon | 3 |
| Discount rate | 0.03 |
| Assumptions | Summary and conclusions derived from abstracted trial-level hazard ratios and reconstructed patient data reported in the abstract; full-text review required to confirm subgroup definitions, harms, toxicity rates, and applicability. |
Benefit-cost fields are assumptions-based unless explicitly source-derived. Treat them as prompts for deeper economic review.
Risk of bias
| Tool | Rapid-abstract-screen informed judgment (not a full formal RoB tool) |
|---|---|
| Verdict | Some concerns / higher uncertainty |
| Notes | Assessment based only on PubMed metadata and abstract. While included trials were phase 3 RCTs, substantial between-trial heterogeneity (high I2 reported) and reliance on reconstructed patient data and indirect comparisons increase uncertainty. Full-text review required to assess randomization integrity, allocation concealment, blinding (if any), crossover, missing data, and harm reporting. |
Harms, equity, conflicts & implementation
| Implementation | Full-text review of methods and harm data, local population size and baseline outcomes estimation, cost and resource use modeling (drugs, infusions, supportive care), and multidisciplinary clinical guideline deliberation. |
|---|---|
| Equity impact | Unclear from abstract. Potential equity concerns exist if access to chemoimmunotherapy or management of increased toxicity differs across populations; subgroup and access data needed. |
| Harms | Abstract does not report detailed toxicity or adverse event rates comparing strategies. Harms and tradeoffs must be extracted from full text and individual trials before clinical or policy changes. |
| Replication | Unknown from PubMed abstract alone; reported pooled analyses include multiple trials but independent prospective confirmation recommended. |
Source links — verify original
Use PubMed and full-text links to confirm methods, population, outcomes, harms, conflicts, and applicability.